Ipamorelin is an investigational compound, not an FDA-approved drug. No approved label, indication, or dosing information exists for it.
Key takeaways
- Ipamorelin has no FDA-approved label and is classified as an unapproved research compound.
- It has a molecular formula of C38H49N9O5 and a molecular weight of 711.9.
- Three clinical trials involving ipamorelin are registered.
- Two identified trials studied ipamorelin for post-operative ileus and recovery of gastrointestinal function, both completed phase 2 studies.
- A third, more recent trial is active but not yet recruiting completion data.
What ipamorelin is
Ipamorelin is a synthetic peptide compound identified by PubChem CID 9831659. It has a defined chemical structure (C38H49N9O5) but does not carry an FDA-approved drug label, so no official description of its mechanism or classification is available from regulatory sources.
Clinical trial footprint
Three clinical trials referencing ipamorelin are registered. Two of these were phase 2 studies examining ipamorelin for post-operative ileus and for recovery of gastrointestinal function after surgery, and both are listed as completed. A third trial, described as a broader research study, is currently active but not recruiting. Because ipamorelin lacks an approved label, these trials reflect research activity rather than established clinical use.